November 5, 2024
Shareholder’s Letter
October 18, 2024
Leadership team preparing the next stages in its development
October 8, 2024
Efficacy validated through updated analyses from CESTO II for smoking cessation. Reduction in craving. Strong commercial potential confirmed.
September 27, 2024
2024 First-half business and earnings update
September 09, 2024
Participation calendar pharma events and institutional investors
July 15, 2024
CESTO II study results
June 17, 2024
Scientific publication of the study on the mechanism of action of NFL-101 conducted by the CEA in ACS Chemical Neuroscience
May 31, 2024
Results of the combined General Meeting of May 30, 2024
May 29, 2024
Presentation of the study results conducted with the CEA at the Albatross congress
May 21, 2024
Positive FDA response following the PRE-IND application for NFL-301 for reducing alcohol consumption
April 18, 2024
NFL Biosciences further strengthens its operational team with the arrival of a Head of Development and Manufacturing
April 12, 2024
Successful capital increase with over €3 million raised
April 11, 2024
NFL Biosciences launches a fundraising round for 3 million euros through a capital increase
April 2, 2024
NFL Biosciences showcases the results of its studies to the scientific and pharmaceutical communities
March 29, 2024
2023 full-year business and earnings update
March 11, 2024
Initiation of analyst coverage by PORTZAMPARC – BNP PARIBAS GROUP
February 13, 2024
NFL Biosciences will present the results of the PRECESTO clinical study at the SRNT conference
January 30, 2024
Success of the study with the CEA
January 9, 2024
2024 Financial Calendar
May 21, 2024
Positive FDA response following the PRE-IND application for NFL-301 for reducing alcohol consumption
December 19, 2023
PRE-IND application filed with the FDA in the United States for NFL-301, indicated for reducing alcohol consumption
October 31, 2023
NFL BIOSCIENCES, a company committed to the fight against tobacco smoking, presents its clinical devlopment advances to help smokers quit (french only)
October 5, 2023
2023 first-half business and earnings update
September 25, 2023
Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results
July 18, 2023
Patent application filed in the United States for reducing alcohol consumption with NFL-301 & preparation of a pre-IND application submission with the FDA
July 5, 2023
Co-founder shareholder further strengthens his position by exercising “BSPCE” warrants
June 29, 2023
GB Holding takes a stake in the company’s capital upon the exercise of share subscription warrants
June 28, 2023
Results of the Combined General Meeting of June 27, 2023
June 21, 2023
Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development
June 9, 2023
Shareholder documentation for the Annual General Meeting (french only)
May 9, 2023
Recruitment completed for the PRECESTO study
April 28, 2023
Availability of the 2022 Annual Report (french only)
April 25, 2023
2022 full-year business and earnings update
February 27, 2023
Changes in the governance
February 22, 2023
Inclusion of the first volunteer in the PRECESTO study
February 20, 2023
NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance
February 2, 2023
Collaboration with the CEA to study the mechanism of action of its drug candidate NFL-101
January 31, 2023
Very successful capital increase for NFL Biosciences with over €3 million raised
January 30, 2023
NFL Biosciences launches a round of fundraising for approximately 2.5 million euros
November 21, 2022
NFL Biosciences takes part in the Société Francophone de Tabacologie congress (french only)
November 8, 2022
Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments
November 2, 2022
New patent application associating NFL-101 with other smoking cessation treatments
October 25, 2022
2022 first-half business and earnings
October 5, 2022
NFL Biosciences partners mith Themis Medicare for the development of NFL-101 in India
June 24, 2022
Participation in the first annual H.C.Wainwright Mental Health Conference (french only)
May 25, 2022
NFL Biosciences, committed to the fight against tobacco smoking, fully supports World No Tobacco Day on May 31st (french only)
May 11, 2022
Decision to approve the issuing of its patent in South Korea
April 11, 2022
Decision to approve the issuing of its patent in China
March 28, 2022
2021 full-year business and earnings
February 2, 2022
Co-development agreement for a drug candidate to reduce alcohol consumption
December 14, 2021
Phase II/III clinical trial launched for smoking cessation
November 17, 2021
Agreement signed with Diverchim to manufacture its active ingredients
October 4, 2021
2021 first-half business and earnings
September 21, 2021
Approval for its patent to be granted in the United States
September 15, 2021
Phase II/III clinical trial for NFL-101 for smokingcessation approved in France
6 septembre 2021
Analyst coverage launched with Invest Securities
July 20, 2021
Implementation of a liquidity contract (french only)
June 30, 2021
NFL Biosciences successfully listed on Euronext Growth Paris (french only)
June 16, 2021
NFL Biosciences launches its Initial Public Offering on Euronext Growth Paris (french only)
June 2, 2021
French smoking cessation innovation approved for Phase II/III clinical trial (french only)